Highlights to be presented at Novo Nordisk's Capital Markets Day 2017 - Seite 2
NOVO NORDISK'S COMMERCIAL PRIORITIES WITHIN DIABETES CARE
Novo Nordisk's commercial priorities within diabetes care will be presented in two dedicated sessions focusing on insulin and GLP-1, respectively. Novo Nordisk has made a clear priority to maximise
its global insulin franchise by focusing on improving both value and volume market shares driven by the innovative project portfolio of new-generation insulin and a commercial focus aligned with
the specific market maturity and market access situation in the individual countries. Novo Nordisk will remain focused on building the leadership within GLP-1, but also on expanding the total GLP-1
market driven by the expected introduction of once-weekly subcutaneous semaglutide. Following the completion of the phase 3a clinical trial programme for once-daily oral semaglutide, the commercial
focus will be directed towards launching in major geographies assuming a successful clinical and regulatory process.
NOVO NORDISK'S AMBITION TO EXPAND THE GLOBAL OBESITY MARKET
By launching Saxenda® in more than 20 countries, Novo Nordisk has become a global market leader within obesity care.
Novo Nordisk has the ambition to further build the obesity market by continuing the global roll-out of Saxenda® as well
as continue its efforts towards having obesity acknowledged as a chronic disease, and thereby expanding the prescriber base.
Following the positive clinical phase 2 results with subcutaneous semaglutide in obesity, Novo Nordisk plans to initiate a phase 3a clinical development, STEP, with once-weekly subcutaneous semaglutide in 2018. The global clinical programme is expected to enrol approximately 4,500 people with obesity and all main trials within the programme will have a duration of 68 weeks. In addition to the phase 3a programme, STEP, Novo Nordisk is also planning to initiate a landmark cardiovascular outcome trial in 2018 with once-weekly subcutaneous semaglutide in obesity with an expected enrolment of approximately 12,500 people.
Lesen Sie auch
MARKET DYNAMICS IN INTERNATIONAL OPERATIONS AND THE USA
The market dynamics for International Operations will be covered with focus on commercial ambitions and the diverse challenges in the five regions. The market opportunity in the USA remains
significant despite a challenging payer environment; Novo Nordisk's expected plans for launching once-weekly semaglutide as well as continuing to improve the position within the insulin market will
be covered.